Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA legislative affairs

Executive Summary

FDA Associate Commissioner for Legislative Activities Melinda Plaisier is appointed Office of International Programs director, but will remain in her job until a successor is found. Walter Batts will continue to oversee international programs as acting director and will assume the vacant post of deputy director after Plaisier moves over. Plaisier will report to senior associate commissioner Murray Lumpkin, MD...

You may also be interested in...



FDA Legislative Affairs Head Sachdev Joins From Energy & Commerce Staff

FDA's Congressional liaison will be one of the Hill staffers who worked on the Prescription Drug User Fee Act reauthorization

Non-Hygiene Personal Care ‘Essential’ In California … For Now; COVID-19 Event Impacts; Cosmetics News In Brief

Santa Monica, CA-based law firm Conkle, Kremer and Engle warns that while all personal-care product businesses appear to be designated “essential” in the Golden State under its statewide “stay at home” order, officials could decide that the policy does not apply to manufacturers of non-hygiene products. More cosmetics news in brief.

Pink Sheet Podcast: US FDA’s Chloroquine EUA And Coronavirus Treatment Accelerator, Novartis Receives No Penalty For Zolgensma Problems

Pink Sheet reporters and editors discuss the effects of the chloroquine emergency use authorization, FDA efforts to speed coronavirus treatment development, and the agency decision against penalizing Novartis over Zolgensma’s data integrity problems. 

UsernamePublicRestriction

Register

PS039738

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel